Wegovy Insurance Coverage in 2025: What's Covered and What's Not

Wegovy (semaglutide 2.4 mg weekly injection) is the most clinically effective weight-loss medication approved by the FDA, producing an average of 15–17% body weight reduction at 68 weeks in the landmark STEP trials. It is also among the most expensive: without insurance, Wegovy carries a retail price of approximately $1,349 per month. For millions of Americans who could benefit medically, that price is the primary barrier to access.

Understanding how to navigate insurance coverage — or find clinically sound alternatives when coverage fails — is one of the most practical skills a patient can develop. This guide walks through every major coverage category in 2025.

The Scale of the Access Problem

The obesity treatment landscape in the United States has been shaped by decades of policy decisions that treated obesity as a lifestyle choice rather than a chronic disease. The result: widespread insurance exclusions for anti-obesity medications (AOMs) that have no equivalent in other chronic disease categories. You would never expect a health insurance plan to exclude metformin for diabetes or lisinopril for hypertension — yet exclusions for weight-loss medications remain the norm rather than the exception.

As of 2025, an estimated 70% of insured Americans cannot obtain meaningful coverage for Wegovy through their health plan. This is beginning to shift — slowly — as actuarial data on the downstream cost savings from treating obesity (reduced cardiovascular events, avoided diabetes, lower orthopedic costs) becomes harder to ignore. But the shift is uneven, and patients must navigate each coverage category individually.

Commercial Insurance (Employer and Marketplace Plans)

Commercial insurance — meaning employer-sponsored plans and individual/family plans purchased through the ACA marketplace — is where Wegovy coverage has grown most significantly, though it remains far from universal.

Large Employer Plans

As of 2025, approximately 50% of large employer health plans (those with 200+ employees) cover at least one FDA-approved anti-obesity medication, including Wegovy or the competing tirzepatide product Zepbound (Eli Lilly). This figure has grown substantially from roughly 25% in 2021, driven by:

• Employer recognition of obesity's cost impact on productivity and healthcare utilization
• Published data from CVOT trials (the SELECT trial, 2023) showing Wegovy reduces major adverse cardiovascular events by 20% in patients with cardiovascular disease and overweight/obesity — enabling coverage under cardiac rather than just weight-loss indications
• Competitive pressure from employers seeking to offer comprehensive benefits

However, coverage among small to mid-size employers (under 200 employees) remains considerably lower — estimated at 20–30% as of 2025. Small self-insured plans rarely cover AOMs due to cost concerns and lack of actuarial sophistication in modeling long-term savings.

What Commercial Coverage Typically Looks Like

When commercial insurance does cover Wegovy, it is typically with conditions:

• Prior authorization (PA): Almost universal. The plan requires your prescriber to document BMI ≥30 (or ≥27 with a qualifying comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or cardiovascular disease), and sometimes a documented history of failed conservative weight-loss attempts.
• Step therapy: Many plans require a trial of a less expensive medication first (commonly phentermine/topiramate or orlistat) before approving Wegovy.
• Specialty tier copay: Wegovy typically lands on Tier 4 or Tier 5 (specialty drug tier), meaning copays can range from $50–$300/month even with coverage — though manufacturer savings programs can reduce this.
• Quantity limits: Plans may limit refills or require ongoing documentation of weight-loss progress.

ACA Marketplace Plans

Coverage on ACA marketplace plans (silver, gold, platinum tiers) is inconsistent and state-dependent. Some state-run exchanges (California, New York, Colorado) have required AOM coverage as a benefit, while federal exchange plans have wider variation. Check your plan's formulary directly — it is searchable on healthcare.gov and most insurance carrier websites.

Medicare

Medicare coverage for Wegovy is the most significant gap in the current landscape, affecting approximately 65 million Americans enrolled in the program.

Under the Medicare Modernization Act of 2003, Medicare Part D (prescription drug benefit) is explicitly prohibited from covering drugs used for weight loss. This exclusion was written into law when obesity pharmacotherapy was limited to relatively modest drugs like orlistat and phentermine. It was never updated as GLP-1 medications demonstrated dramatically superior efficacy.

The SELECT Trial and Cardiovascular Indication Carve-Out

The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) was a watershed moment. This 17,604-patient cardiovascular outcomes trial demonstrated that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE — nonfatal MI, nonfatal stroke, cardiovascular death) by 20% in patients with established cardiovascular disease and overweight or obesity, with no diabetes. The FDA subsequently approved Wegovy for this cardiovascular risk reduction indication in March 2024.

CMS (Centers for Medicare & Medicaid Services) issued guidance in 2024 stating that Medicare Part D plans may cover Wegovy when prescribed specifically for cardiovascular risk reduction in patients meeting the SELECT trial criteria — not for weight loss per se. This created a narrow but important coverage pathway for Medicare patients with qualifying cardiovascular history.

The TROA Act

The Treat and Reduce Obesity Act (TROA) is pending Congressional legislation that would remove the Medicare weight-loss drug exclusion and allow Part D plans to cover FDA-approved AOMs. Multiple versions of the bill have been introduced since 2012 without passing. As of 2025, TROA remains in committee, with advocacy groups continuing to push for passage. If enacted, it would represent the most significant expansion of obesity treatment access in the Medicare program's history. Patients and advocates can track the bill's status through the Obesity Action Coalition.

Medicare Supplement (Medigap) Plans

Medigap policies supplement Original Medicare (Parts A and B) but do not cover Part D drugs. They cannot fill the Wegovy gap. Some Medicare Advantage plans (Part C) have begun adding limited AOM benefits, particularly for the cardiovascular indication — check your specific Advantage plan's formulary.

Medicaid

Medicaid AOM coverage is determined state by state, since Medicaid operates as a federal-state partnership with each state setting its own drug formulary and coverage rules.

As of 2025:

• States with Wegovy coverage: Approximately 15–18 states have added Wegovy or tirzepatide to their Medicaid preferred drug lists, including California, New York, Illinois, Massachusetts, and several others. Coverage often requires PA with documented BMI criteria and comorbidities.
• States without AOM coverage: The majority of states still do not cover Wegovy on Medicaid, citing cost. At ~$1,349/month per patient, widespread coverage represents substantial budget exposure for state programs.
• Checking your state: Your state Medicaid agency's website or a benefits navigator (available free through navigator.cms.gov) can confirm current formulary status.

Novo Nordisk Savings Programs

Novo Nordisk (the manufacturer of Wegovy) offers patient assistance programs that can dramatically reduce out-of-pocket costs:

Wegovy Savings Card (Commercial Insurance)

For patients with commercial (employer or marketplace) insurance that covers Wegovy, the Novo Nordisk savings card can reduce the copay to as low as $0 per month (or a small fixed copay) for eligible patients. Eligibility requires:

• Commercial (private) insurance coverage for Wegovy
• Not enrolled in any government-funded program (Medicare, Medicaid, CHIP, VA, TriCare)
• US resident

This card is available directly through the NovoCare website or via your prescriber's office. It is worth pursuing even if your copay is listed as low — the card typically eliminates the copay entirely for the first year and reduces it substantially thereafter.

NovoCare Patient Assistance Program

For patients with no insurance or government insurance who meet income eligibility criteria (generally ≤400% of the federal poverty level), NovoCare offers Wegovy at no cost. Applications are processed through the NovoCare portal and require income documentation. Processing typically takes 2–4 weeks.

Step Therapy: What It Is and How to Fight It

Step therapy (also called "fail first") is a coverage requirement forcing patients to try and fail one or more less expensive medications before the insurer approves the drug prescribed by their physician. For Wegovy, this commonly means a required trial of phentermine/topiramate (Qsymia) or bupropion/naltrexone (Contrave) — medications with considerably lower efficacy.

Step therapy can delay access to effective treatment by months. Most states have enacted step therapy override laws that allow physicians to appeal step therapy requirements when:

• The required drug is contraindicated for the patient
• The patient previously tried and failed the required drug
• The required drug is clinically not appropriate for the patient's specific condition
• Delay of treatment poses a serious risk to patient health

Your prescriber can submit a step therapy override request with clinical documentation. Success rates on well-documented appeals are meaningful — work closely with your physician's office to build the strongest possible appeal if you face this barrier.

Prior Authorization Appeals

If Wegovy is denied on prior authorization, you have formal appeal rights:

1. Internal appeal: Request an internal appeal in writing within 30–60 days of denial. Provide additional clinical documentation from your prescriber supporting medical necessity.
2. External review: If the internal appeal is denied, you can request an independent external review — required under the ACA for non-grandfathered health plans. External reviewers reverse insurer denials approximately 40% of the time for specialty drugs.
3. State insurance commissioner: If you believe your insurer is improperly applying coverage rules, file a complaint with your state's department of insurance.

Telehealth and Compounded Alternatives

For patients who cannot access Wegovy through insurance and do not qualify for manufacturer assistance, several alternatives exist:

• Compounded tirzepatide: Tirzepatide (the active ingredient in Zepbound and Mounjaro) remains on the FDA shortage list as of 2025, meaning compounded versions are legally available through compliant 503A pharmacies. Compounded tirzepatide through telehealth platforms is typically priced at $200–$500/month — a fraction of brand-name cost — and the SURMOUNT-5 trial data suggests tirzepatide may produce greater weight loss than semaglutide.
• Generic oral semaglutide: Rybelsus (oral semaglutide 14 mg, FDA-approved for type 2 diabetes) may be prescribed off-label for weight management at a lower cost point than injectable Wegovy in some coverage scenarios.
• Combination programs: Metabolic programs combining lower-dose GLP-1 medications with structured nutrition, behavioral support, and metabolic monitoring can achieve meaningful outcomes at lower cost than full-dose Wegovy without insurance.

Practical Next Steps for Patients

If you're navigating Wegovy coverage, work through these steps methodically:

1. Check your plan formulary — log into your insurance portal and search for "semaglutide" or "Wegovy" in the drug formulary search. Note the tier and any PA requirements.
2. Work with your prescriber on PA — provide complete documentation of your BMI, comorbidities, and any prior weight-loss attempts. The more thorough the PA submission, the higher the approval probability.
3. Apply for the savings card immediately if you're commercially insured — don't wait until you receive your first bill.
4. If denied, appeal — the appeal process has real success rates. Don't accept the first denial as final.
5. Explore compounded tirzepatide if cost is prohibitive and you don't qualify for assistance programs.
6. Consult a patient advocate — non-profit organizations including the Obesity Action Coalition offer free support for patients navigating AOM coverage barriers.